Table 3 Clinical characteristics of study HFN1A-MODY patients
Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | |
|---|---|---|---|---|---|
Age at diagnosis (ys) | 2.5 | 7.2 | 17.8 | 11.3 | 10.7 |
BMI at diagnosis (Z-score) | 0.5 | 0.2 | 1.4 | -1.1 | 1.9 |
HbA1c at onset (%) | 5.1 | 5.5 | 7.4 | 10.7 | 7.3 |
HbA1c at onset (mmol/mol) | 32 | 37 | 57 | 93 | 56 |
OGTT: 0ˈ glucose (mmol/l) | N/A | 5.89 | 7.67 | N/A | 7.50 |
OGTT: 120ˈ glucose (mmol/l) | N/A | 8.94 | 15.0 | N/A | 18.50 |
C-peptide at onset (ng/dl) | 0.30 | 2.66 | 1.38 | 2.84 | 2.00 |
Weight at birth (kg) | 2.720 | 3.150 | 2.440 | 3.680 | 2.500 |
HLA | |||||
DR3 and/or DR4 | No | Yes | No | No | No |
Autoantibodies | No | No | No | No | No |
Treatment | Insulin | Insulin | Diet | Gliclazide | Gliclazide |